In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate

Document Type : Original Article


1 Department of Nuclear Medicine Royal North Shore Hospital St Leonards 2065 Sydney, NSW , AUSTRALIA

2 Department of Nuclear Medicine Prince of Wales Hospital Randwick 2031 NSW

3 Institute of Medical Physics University of Sydney Sydney 2006 NSW

4 Department of Nuclear Medicine Royal North Shore Hospital St Leonards 2065 NSW

5 Department of Nuclear Medicien Royal North Shore Hospital St Leonards 2065 NSW


Objective(s):Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “No Carrier Added” (NCA) 177Lu. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate with NCA 177Lu (“NCA-LuTATE”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on our initial studies on aspects of the biodistribution and dosimetry of NCA-LuTATE from gamma camera 2D whole body (WB) and quantitative 3D SPECT (qSPECT) 177Lu imaging.
Methods: Thirteen patients received 39 NCA-LuTATE injections. Extensive WB planar and qSPECT imaging was acquired at approximately 0.5, 4, 24 and 96 h to permit estimates of clearance and radiation dose estimation using MIRD-based methodology (OLINDA-EXM).
Results:The average amount of NCA-Lutate administered per cycle was 7839±520 MBq. Bi-exponential modelling of whole body clearance showed half lives for the fast & slow components of t½=2.1±0.6 h and t½=58.1±6.6 h respectively. The average effective dose to kidneys was 3.1±1.0 Gy per cycle. In eight patients completing all treatment cycles the average total dose to kidneys was 11.7±3.6 Gy.
Conclusions: We have shown that NCA-LuTATE has an acceptable radiation safety profile and is a suitable alternative to Carrier-Added 177Lu formulations. The fast component of the radiopharmaceutical clearance was closely correlated with baseline renal glomerular filtration rate, and this had an impact on radiation dose to the kidneys. In addition, it has less radioactive waste issues and requires less peptide per treatment.


Main Subjects

1. Bailey DL, Hennessy TM, Willowson KP, Henry EC, Chan DL, Aalani A, et al. In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging. EJNMMI Phys. 2015;2(1):20-36.
2. Aslani A, Snowdon G, Bailey D, Schembri G, Baily E, Pavlakis N, et al. Lutetium-177 DOTATATE production with an automated radiopharmaceutical synthesis system. Asia Ocean J Nucl Med Biol. 2015;3(2):107-15.
3. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319-25.
4. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S-61S.
5. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023-7.
6.Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37(3):538-46.
7. Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Wildstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33-41.
8. Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212-25.
9. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138-46.
10. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides. Q J Nucl Med Mol Imaging. 2006;50(4):288-95.
11. Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406-16.
12. Limouris G, Paphiti MI, Moulopoulou L, McCready RV. Comparison and evaluation of nca and ca Lu-177-[DOTA (0), Tyr3] octreotate in (GEP-NETs) treated patients. Eur J Nucl Med Mol Imag. 2014;41(233):S551.